ClinicalTrials.gg
RecruitingNCT06049771Updated Sep 22, 2023

The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carbapenem Resistant Enterobacteriaceae Bloodstream Infection

An interventional study of Collect blood sample in Carbapenem-resistant Enterobacteriaceae, sponsored by Phramongkutklao College of Medicine and Hospital. Recruiting at 1 site in Thailand. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Phramongkutklao College of Medicine and Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Sepsis with a site in Thailand — 7 open to participants now, 8 under way, none of them phase 3. Sepsis · Thailand.

Planned enrollment
21st of 27
72 · median 197
Started
2023
the only one that year
No phase
15 of 38
3 open now
Registered
28th of 38
by date
Lead sponsor
2 of 38
Phramongkutklao College of Medicine and Hospital

Among the 38 studies in Sepsis with a site in Thailand, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2023, is one of 15 with no phase, and was the 28th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

7 of the 38 studies in Sepsis with a site in Thailand are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Sepsis with a site in Thailand, or all of them as a file.
02

Study summary

Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%. The National Antimicrobial Resistance Surveillance Center, Thailand (NARST) reported CRE increased from 1.1% to 17.9%. For carbapenemase producing CRE in Thailand was reported blaNDM 47.33%, blaOXA-48 43.33% and blaNDM+blaOXA-48 6.67%.

Tigecycline (TGC) was a glycylcyclines antibiotics. High dose tigecycline (HD-TGC) loading dose 200 mg then TGC 100 mg q 12 h via intravenous improve clinical cure in critically ill patients and reduce mortality in carbapenem resistance Klebsiella pneumoniae bloodstream infection compared with standard dose therapy. TGC has susceptibility to CR-KP 79.6% and has an activity to blaNDM, blaKPC and blaOXA-48 carbapenemase producing CRE. However, TGC has clearance (CL) 0.2-0.3 L/h/kg, and high volume of distribution (vd) 2.8-13 L/kg resulted in low levels of TGC in plasma. Moreover, the pharmacokinetics of TGC in critically ill was limited and inconsistent with the previous study. Now pharmacokinetics-pharmacodynamics index (PK/PD index) of TGC for CRE bloodstream infection was not reported. This study aims to study the population pharmacokinetic and PK-PD index of TGC in patients who were CRE bloodstream infection to increase the success rate of treatment.

Read the detailed description

Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%. The National Antimicrobial Resistance Surveillance Center, Thailand (NARST) reported the carbapenem resistance Klebsiella pneumoniae (CR-KP) prevalence increased from 1.1% in 2000 to 17.9% in 2021 and the carbapenem resistance Escherichia coli was increased from 0.6% in 2000 to 5% in 2021. For carbapenemase producing CRE in Thailand was reported blaNDM 47.33%, blaOXA-48 43.33%, and blaNDM+blaOXA-48 6.67%. Ceftazidime-avibactam was first-line of treatment for CRE bloodstream infection recommended by Infectious Disease Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections but ceftazidime-avibactam was limited activity to blaNDM carbapenemase producing CRE.

Tigecycline (TGC) was a glycylcyclines antibiotics. TGC was approved for U.S.FDA for complicated intra-abdominal infection, complicated skin and skin structure infection and community acquired pneumonia with loading dose TGC 100 mg then TGC 50 mg q 12 h via intravenous. High dose tigecycline (HD-TGC) loading dose 200 mg then TGC 100 mg q 12 h improve clinical cure in critically ill patients and reduce mortality in CR-KP bloodstream infection compared with standard dose therapy. TGC has susceptibility to CR-KP 79.6% and has an activity to blaNDM, blaKPC and blaOXA-48 carbapenemase producing CRE. However, TGC has clearance (CL) 0.2-0.3 L/h/kg, and high volume of distribution (vd) 2.8-13 L/kg resulted in low levels of TGC in plasma. Moreover, the pharmacokinetics of TGC in critically ill was limited and inconsistent with the previous study. Now pharmacokinetics-pharmacodynamics index (PK/PD index) of TGC for CRE bloodstream infection was not reported. This study aims to study the population pharmacokinetic and PK-PD index of TGC in patients who were CRE bloodstream infection to increase the success rate of treatment.

03

Conditions studied

  • Carbapenem-resistant Enterobacteriaceae

Browse trials for

Keywords

  • Tigecycline
  • Population pharmacokinetics
  • pharmacokinetics-pharmacodynamics index
  • bloodstream infection
  • CRE
  • Carbapenem-resistant Enterobacteriaceae
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 20 years and older who were admitted at Phramongkutklao Hospital
  2. Patients who were diagnosed bloodstream infection with CRE and who were sepsis or septic shock
  3. Patients who received tigecycline loading dose 200 mg infusion for 1 hour and following maintenance dose 100 mg every 12 h infusion for 1 hour at least 48 hours and grant for blood collection

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or Breastfeeding
  2. Patients who cannot tolerant to the toxicity of tigecycline for example to tigecycline or any component of the formulation
  3. Patients who were infected with more than one isolated in blood culture at the same time
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Patients who were infected caused by CRE bloodstream infection and were treated with tigecycline. Blood samples were collected.

    Other: Collect blood sample

Interventions

  • OtherCollect blood sample

    Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose

06

What researchers measure

Primary outcomes

  1. rate constant for tigecycline distribution from the central to the peripheral compartment

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  2. rate constant for tigecycline distribution from the peripheral to central the compartment

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  3. elimination rate constant

    Population pharmacokinetic parameter of tigecycline

    Time frame: up to 6 months

  4. intercompartmental clearance

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  5. total clearance

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  6. volume of central compartment

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  7. volume distribution of peripheral compartment

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  8. steady state volume distribution

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  9. Area under the plasma concentration versus time curve (AUC)

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

  10. Peak Plasma Concentration (Cmax)

    Population pharmacokinetic parameter outcome of tigecycline

    Time frame: up to 6 months

Secondary outcomes

  1. PK/PD index for CRE bloodstream infection

    pharmacokinetics-pharmacodynamics parameter of tigecycline for CRE bloodstream infection

    Time frame: up to 6 months

  2. Rate of mortality

    Alive or death

    Time frame: 7,14 and 28 days

  3. Number of Participants with the clinical outcome

    Clinical cure or clinical failure Clinical cure was defined as the resolution or improvement of all signs and symptoms present at study entry Clinical failure was defined as any one or more following circumstances: persistent or worsened signs and symptoms, a new clinical findings consistent with the progression of infection.

    Time frame: 14 days

  4. Number of Participants with the microbiological outcome

    Eradicated or persistent evaluated by culture of bloodstream

    Time frame: 7 days

  5. Genotype classification of carbapenemase producing CRE

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
  • Phramongkutklao Hospital
    Ratchathewi, Bangkok 10400, Thailand
    Recruiting
    • Sirapat Somsirikarnjanakoon, PharmD. · Contactsirapat.rx@gmail.com · 0982511524
    • Wichai Santimaleeworagun, PhD · Contactswichai1234@gmail.com · 0814426713
    • Sirapat Somsirikarnjanakoon, PharmD · Principal investigator
    • Wichai Santimaleeworagun, PhD · Principal investigator
    • Worapong Nasomsong, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for May 2025, 20 months later.

Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 20 months is below that.

Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Sep 22, 2023
StartEst.
Sep 17, 2023
Primary completionEst.
May 31, 2025
CompletionEst.
Jun 30, 2025
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06049771
Lead sponsor
Phramongkutklao College of Medicine and Hospital
Collaborators
Silpakorn University
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Sep 17, 2023 (estimated)
Primary completion
May 31, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Sep 22, 2023

Study contacts

Sirapat Somsirikarnjanakoon, PharmD.
Contact
sirapat.rx@gmail.com
0982511524
Wichai Santimaleeworagun, PhD.
Contact
swichai1234@gmail.com
0814426713
Sirapat Somsirikarnjanakoon, PharmD.
study chair · Faculty of Pharmacy, Silpakorn University
Wichai Santimaleeworagun, PhD.
study director · Faculty of Pharmacy, Silpakorn University
Worapong Nasomsong, MD.
study director · Phramongkutklao College of Medicine and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion